Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab
- Resource Type
- Article
- Source
- In
Clinical Lung Cancer September 2023 24(6):e205-e213 - Subject
- Language
- ISSN
- 1525-7304